세계의 통풍 치료 시장 : 약제 클래스별, 병상별, 투여 경로별, 유통 채널별, 지역별, 기회, 예측(2018-2032년)

Global gout therapeutics market is projected to witness a CAGR of 6.91% during the forecast period 2025-2032, growing from USD 3.02 billion in 2024 to USD 5.15 billion in 2032. The global gout therapeutics market growth is projected to rise owing to the rising prevalence of gout and advancements in treatment options.

The global gout treatment market is experiencing fast expansion because of rising gout cases and rising body uric acid levels. The combination of rising obesity rates and unhealthy eating patterns alongside aging populations has resulted in more gout cases, thus driving the need for better treatment solutions. Research scientists continue to develop new therapeutic methods while the market provides multiple treatment approaches through urate-lowering medications, together with anti-inflammatory and pain control drugs. The leading companies in the industry dedicate funds to create innovative solutions that enhance health results for gout patients, particularly those who experience persistent or challenging-to-treat gout. Medical professionals identify biological therapies, along with new inhibitors, as revolutionary solutions that would replace current standard treatment approaches. The market growth receives support from enhanced diagnostic systems along with increasing public awareness of gout, which allows for prompt treatment interventions. The advanced medical systems in developed nations enable them to implement modern gout treatment options, which create new growth possibilities through wider healthcare availability. The market's competitive environment gets shaped by pharmaceutical companies obtaining regulatory approvals while establishing strategic partnerships. Additionally, to support the gout therapeutics market, companies are expanding their presence in other countries. For instance, in December 2024, Eisai Co., Ltd. received approval from the National Medical Products Administration in China for URECE to treat gout patients with hyperuricemia.

Rising Gout Cases Drive Therapeutic Market Growth

The increasing prevalence of gout worldwide drives substantial market expansion through multiple contributing factors. People eat purine-rich foods while drinking more alcohol and avoiding exercise, which together raises uric acid levels that cause gout. The worldwide rise in gout patients emerges because populations grow older, obesity rates increase, and hypertension and diabetes become more prevalent, since these conditions serve as known disease risk factors. The growing number of disease cases, along with improved diagnostic methods and increased disease knowledge, created substantial demand for traditional and novel treatment approaches. Pharmaceutical companies develop new therapeutic solutions and enhance medication distribution to emerging regions where gout rates continue to rise. The market experiences substantial growth because manufacturers and healthcare providers focus on developing solutions that treat both sudden gout flare-ups and ongoing disease control.

Furthermore, to increase the prevalence of gout therapy among people, companies participate in awareness programs. For instance, in May 2025, Atom Therapeutics Ltd. joined the Gout Education Society in Gout Awareness Day programs to educate people about the factors and treatment of this disease.

Advancements in Therapeutic Drugs Boost Market Demand

The gout therapeutics market is expanding quickly because of new drug development alongside advanced treatment solutions. Modern next-generation xanthine oxidase inhibitors, together with improved uricosuric agents and biologic therapies (recombinant uricase enzymes such as pegloticase), have revolutionized disease management for refractory cases. Modern gout treatments offer better effectiveness together with fewer side effects and make it easier for patients to stick with their treatment plans. The use of combination therapies along with personalized medicine approaches leads to better treatment outcomes. Standard medicinal therapies receive additional research and development resources from pharmaceutical companies for developing solutions that address patients who do not respond to these treatments. Advanced therapy across the globe is rising because healthcare organizations apply regulatory-approved treatment options. The ongoing development creates broader treatment accessibility while driving market expansion, which establishes gout therapeutics as a fast-growing pharmaceutical industry sector. Additionally, to support a pharmaceutical company in the advanced treatment of gout. For instance, in May 2025, XORTX Therapeutics Inc. announced plans to execute a non-brokered private placement that would produce USD 3 million by selling common share units. The money from this offer supports two main objectives: funding the gout therapeutic program development and meeting essential business requirements. XORTX pursues this strategic initiative to achieve better financial stability while advancing its pharmaceutical industry development work, which targets gout and kidney disease therapies.

Hospital Pharmacies Hold Largest Global Gout Therapeutics Market Shares

Hospital pharmacies hold the strongest position as the primary distribution channel, which generates the highest revenue in the gout therapeutics market. The market leader derives its position through multiple fundamental reasons, which include that hospitals are essential for managing severe gout conditions and biologic infusions such as pegloticase for difficult-to-treat chronic gout and sudden flare-ups. Medical facilities specifically manage high-cost treatments, together with injectable drugs, which need professional medical monitoring. Hospitalizations for gout-related complications, including tophaceous gout and kidney stones, have increased, thus increasing patient demand through this distribution channel. The pattern shows strong prevalence in developed countries that possess advanced healthcare systems due to hospitals' function as primary centers for both initial diagnosis and treatment commencement. Hospital pharmacies continue to lead the market because they provide specialized treatments with integrated physician supervision for acute cases, despite retail and online pharmacies expanding their presence in chronic maintenance medication. The gout treatment ecosystem requires these institutions to function as essential components for advanced therapies and acute interventions.

For instance, in May 2025, ANI Pharmaceuticals, Inc. announced a Phase 4 clinical trial at Massachusetts General Hospital, which evaluates the safety profile and treatment effectiveness of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for acute gout flare management. The medical indication for Cortrophin Gel includes brief use as an auxiliary treatment during acute gouty arthritis attacks. Patients should avoid using Cortrophin Gel through intravenous routes.

North America Dominates the Gout Therapeutic Market

The North America gout therapeutic market leads because of various factors, which include high gout rates, together with modern healthcare systems and substantial R&D funding. The United States, together with Canada, forms the main gout patient base because obesity, combined with unhealthy eating and growing age populations, leads to increased gout cases. The strong pharmaceutical industry, together with a solid regulatory system, enables speedy approval and widespread use of new medical treatments. The healthcare system delivers modern treatments to numerous patients while widespread gout awareness programs fuel market growth. Through insurance and reimbursement systems, patients receive affordable treatment options that become accessible to them. North America maintains its position as the leading gout therapeutic market because fresh biological and urate-lowering therapies entered the market while clinical trials continue. Multiple market-driving factors combine to make this region the most significant and dynamic gout treatment market. Additionally, to support this region, market players have successfully launched their clinical trials to increase market growth. For instance, in June 2025, Zydus Lifesciences Limited announced its phase II clinical trial of NLRP3 inhibitor Usnoflast (ZYIL1) in patients with Amyotrophic Lateral Sclerosis.

Impact of U.S. Tariffs on the Global Gout Therapeutics Market

The U.S. tariff effects on the global gout therapeutics market are due to instability through elevated prices and disrupted supply chain operations. Generic gout medications, including allopurinol and febuxostat, utilize active pharmaceutical ingredients (APIs) provided from China and India. These manufacturers of gout therapeutics will be subject to major price increases if tariffs are introduced on APIs. In turn, this will likely lead to countrywide shortages (no medicine at any price), increased treatment costs, and limited access for uninsured populations, including ancillary medications that treat other annual curative care costs, mostly statins and diuretics. Eventually, supply chains will have to change manufacturers, but that is a long way off, especially considering a market that is likely already saturated and the costs of changing their supply chain limit affordability and pressure healthcare systems and access. The long-term impact depends on tariff exemptions and how quickly supply chains adapt to new trade policies.

Key Players Landscape and Outlook

The global market for gout treatment maintains a constant state of innovation due to companies striving to finish ahead of their competitors in drug development, especially for refractory and chronic gout with advanced biologics and enhanced urate-lowering therapies. The fast-paced market will see rising competition from new technologies and partnerships between industry players. In March 2023, Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Sobi) declared the Phase 3 DISSOLVE I & II trial results that demonstrated positive outcomes for SEL-212 doses in adult patients with chronic refractory gout.

In August 2024, Arthrosi Therapeutics Inc., a late-stage biotechnology firm that created an advanced URAT1 inhibitor for gout treatment, received FDA Fast Track Designation for AR882 to treat clinically detectable tophi in gout patients.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Gout Therapeutics Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.2.1.2. Corticosteroids
    • 5.2.1.3. Colchicine
    • 5.2.1.4. Urate-Lowering Agents
    • 5.2.1.5. Biologics
    • 5.2.1.6. Other Drug Classes
  • 5.2.2. By Disease Condition
    • 5.2.2.1. Acute Gout
    • 5.2.2.2. Chronic Gout
  • 5.2.3. By Route of Administration
    • 5.2.3.1. Oral
    • 5.2.3.2. Parenteral
    • 5.2.3.3. Other Routes
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
    • 5.2.4.4. E-commerce
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Drug Class
  • 5.3.2. By Disease Condition
  • 5.3.3. By Route of Administration
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Gout Therapeutics Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Drug Class
    • 6.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 6.2.1.2. Corticosteroids
    • 6.2.1.3. Colchicine
    • 6.2.1.4. Urate-Lowering Agents
    • 6.2.1.5. Biologics
    • 6.2.1.6. Other Drug Classes
  • 6.2.2. By Disease Condition
    • 6.2.2.1. Acute Gout
    • 6.2.2.2. Chronic Gout
  • 6.2.3. By Route of Administration
    • 6.2.3.1. Oral
    • 6.2.3.2. Parenteral
    • 6.2.3.3. Other Routes
  • 6.2.4. By Distribution Channel
    • 6.2.4.1. Hospital Pharmacies
    • 6.2.4.2. Retail Pharmacies
    • 6.2.4.3. Online Pharmacies
    • 6.2.4.4. E-commerce
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Gout Therapeutics Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 6.3.1.2.1.2. Corticosteroids
        • 6.3.1.2.1.3. Colchicine
        • 6.3.1.2.1.4. Urate-Lowering Agents
        • 6.3.1.2.1.5. Biologics
        • 6.3.1.2.1.6. Other Drug Classes
      • 6.3.1.2.2. By Disease Condition
        • 6.3.1.2.2.1. Acute Gout
        • 6.3.1.2.2.2. Chronic Gout
      • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.3.1. Oral
        • 6.3.1.2.3.2. Parenteral
        • 6.3.1.2.3.3. Other Routes
      • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.4.1. Hospital Pharmacies
        • 6.3.1.2.4.2. Retail Pharmacies
        • 6.3.1.2.4.3. Online Pharmacies
        • 6.3.1.2.4.4. E-commerce
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Gout Therapeutics Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Gout Therapeutics Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Gout Therapeutics Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Gout Therapeutics Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

• 18.1. Clinical Trials
• 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Merck & Co., Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Sanofi S.A.
  • 21.3.3. Regeneron Pharmaceuticals, Inc.
  • 21.3.4. Novartis AG
  • 21.3.5. AstraZeneca PLC
  • 21.3.6. Astellas Pharma Inc.
  • 21.3.7. Takeda Pharmaceutical Company Limited
  • 21.3.8. Hikma Pharmaceuticals PLC
  • 21.3.9. BioCryst Pharmaceuticals, Inc.
  • 21.3.10. Selecta Biosciences Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer